Opko snags Ophthalmic Technologies

Article

Opko Health has entered into an agreement to acquire the Canadian company, Ophthalmic Technologies.

Opko Health has entered into an agreement to acquire the Canadian company, Ophthalmic Technologies.

Ophthalmic Technologies markets a complete line of ophthalmic ultrasound and imaging products and its SLO/OCT system provides a flexible platform for processing a wide variety of diagnostic tests.

According to the terms of the agreement, Opko has purchased one-third of the outstanding common shares of the company and has received an exclusive option to purchase the remaining shares over a period of six months.

Opko has also hired Steven Verdooner as Executive Vice President of Instrumentation, a newly created position.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.